Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWIFT tirzepatide study in schizophrenia
ACTRN12626000530325Phase 3Not yet recruiting
- Sponsor
- The University of Queensland
- Start
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in obesity, schizophrenia and schizoaffective disorder comparing Tirzepatide + routine care with Placebo + routine care (2 arms). Primary endpoint: Percentage of body weight change. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
03
Conditions
obesityschizophreniaschizoaffective disorder
Beyond the preview
Go deeper on ACTRN12626000530325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000530325.